| T Cell Engager (TCE) bispecific antibodies refer to a type of bispecific antibody that can simultaneously bind to tumor-associated antigens (TAA) and CD3 on T cells. The design aims to direct T cells to tumor cells, enabling them to kill tumor cells effectively. Currently, TCEs have achieved breakthroughs in hematologic malignancies. For instance, in blood cancers, there are already approved drugs targeting CD3 in combination with CD19, CD20, and BCMA, which have shown remarkable efficacy. Building on this foundation, TCE drugs are advancing into solid tumors and autoimmune indications. CD3 is a multimeric protein complex, also known as the T3 complex, composed of four different polypeptide chains: epsilon (ε), gamma (γ), delta (δ), and zeta (ζ). These chains assemble as three pairs of dimers (εγ, εδ, ζζ) to perform their functions. Genomeditech can provide CD3-targeted overexpression cell lines, functional cell lines, antibodies, and other resources for the in vitro activity validation of CD3-targeting antibodies. |  |
